ArticleCPT: pharmacometrics & systems pharmacology2026
A Tutorial on the Development of a Physiologically Inspired PKRO Model for Monoclonal Antibodies.
Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Tutorial on the Development of a Physiologically Inspired PKRO Model for Monoclonal Antibodies.CPT: pharmacometrics & systems pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modeling and simulations are indispensable tools to describe pharmacokinetics (PK) and pharmacodynamics to support monoclonal antibody (mAb) development. The linear PK of mAbs is commonly described by a 2-compartment PK model, while the nonlinear PK often observed at low doses is described by target mediated drug disposition (TMDD) models. Since target binding is the primary pharmacology of mAbs and receptor occupancy (RO) could impact PK through TMDD, it is desirable to have a simple mechanistic model to simultaneously describe both PK, including TMDD, and RO at the site of action (SoA). In this tutorial, we introduce a physiologically inspired PKRO (piPKRO) model for mAbs targeting membrane receptors. The linear PK part (referred to as the piPK model) is modified from the classical 2-compartment PK model to include using the physiological compartment volumes, adding drug clearance in extravascular compartments, describing mAb concentration in tissues reflecting measured partition coefficients, and target expression and drug binding based on the location of target expression. A few macroparameters including P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.